Aspartoacylase

Aspartoacylase is an enzyme that plays a crucial role in the nervous system's functioning by breaking down N-acetylaspartate (NAA) into aspartate and acetate. This process is vital for the maintenance and development of myelin, the protective sheath that surrounds neurons and is essential for the rapid transmission of nerve impulses. The gene responsible for encoding aspartoacylase is ASPA, located on human chromosome 17.

Function

Aspartoacylase's primary function is to hydrolyze N-acetylaspartate (NAA) into aspartate and acetate within the central nervous system (CNS). Acetate produced by this reaction is a critical substrate for lipid synthesis in the brain, contributing to the formation and maintenance of myelin. The exact physiological role of NAA and its metabolism by aspartoacylase, however, is still under investigation, with studies suggesting it may also be involved in neuronal signaling and osmoregulation.

Clinical Significance

The deficiency of aspartoacylase is directly linked to Canavan disease, a rare inherited genetic disorder that causes progressive damage to the nerve cells in the brain. This autosomal recessive disorder is characterized by a significant accumulation of N-acetylaspartate due to the lack of functional aspartoacylase, leading to spongy degeneration of the white matter in the brain. Symptoms of Canavan disease include developmental delay, seizures, and motor skill impairment, with onset typically occurring in infancy.

Genetic Aspects

The ASPA gene mutations that lead to aspartoacylase deficiency and, consequently, Canavan disease, vary widely. These mutations can result in the production of a nonfunctional version of the enzyme or decrease its activity, preventing the normal breakdown of NAA. Genetic testing can identify carriers of the disease and help in prenatal diagnosis.

Research Directions

Research into aspartoacylase and its functions has opened new avenues for understanding brain metabolism and the pathophysiology of Canavan disease. Efforts are underway to explore potential treatments, including gene therapy, enzyme replacement therapy, and substrate reduction therapy, aiming to restore normal levels of NAA or compensate for the lack of aspartoacylase activity. These approaches are still in the experimental stages but hold promise for future therapeutic strategies.